All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development

Kura Oncology earns $45M milestone payment from Kyowa Kirin for ziftomenib NDA submission in acute leukemias
Small molecule, leukemia, cancer, milestone payment - Read more

THE GOOD
Clinical Trials

AstraZeneca's Breztri (budesonide/formoterol/glycopyrronium) improved lung function in Ph3 trials for uncontrolled asthma, potentially expanding beyond chronic obstructive pulmonary disorder approval
Small molecule, asthma - Read more

Recursion's REC-4881, an allosteric MEK1/2 inhibitor, shows 43% polyp reduction in Ph1b/2 trial for Familial Adenomatous Polyposis, with manageable safety profile
Small molecule, familial adenomatous polyposis - Read more

PRESENTED BY AMBIENT BIOSCIENCES
Break Free from the Cold Chain with Ambient-Stable Reagents

Are you ready to eliminate complex reagent lyophilization workflows and cold chain logistics from your operations?

Ambient Biosciences’ innovative reagent stabilization platform uses a gentle, freeze-free process to stabilize sensitive biomolecules - like enzymes, antibodies, nucleic acids, and master mixes - with minimal optimization for room temperature storage and shipping.

Our shelf-stable reagents are ready when you are: simply grab them from the shelf, rehydrate, and start your assay.

Get your FREE sample kit today and see how our stabilized reagents can transform your workflows.

✅ More Good News ✅

THE GOOD
Earnings & Finances

BioMarin's EPS exceeded estimates by 37%, with revenue meeting expectations and projected 7.1% annual growth
Big pharma earnings - Read more

Amgen's Stelara biosimilar generated $150 million in first quarter sales, part of $735 million total biosimilar revenue
Big pharma earnings, monoclonal antibody, biosimilar, autoimmune disease - Read more

THE GOOD
Fundraises

Pathos AI $283M out of planned $400M equity raise, healthcare AI company backed by AstraZeneca
AI, drug development, cancer, precision medicine - Read more

Epicore Biosystems $6M Series B, developing sweat-sensing wearables for hydration monitoring and biomarker validation for kidney health
Medical device, wearable device, biomarker - Read more

CND Life Sciences raises $13.5M Series A for neurodiagnostics, helping diagnose Parkinson's and other synucleinopathies with Syn-One Test
Disease screening, diagnostics, neurodegenerative disease - Read more

QCDx $7M financing, liquid biopsy company developing technology for cancer detection through circulating tumor cells
Diagnostics, cancer detection/screening - Read more

Adial Pharmaceuticals $2.75M warrant inducement, clinical-stage biopharmaceutical company developing addiction treatment therapies
Small molecule, alcohol use disorder - Read more

THE GOOD
Investments

Aviva Capital Partners announces plans for £1B ($1.3B) build cancer research and treatment hub in London, in effort to retain and attract life science talent
Research center, new facility - Read more

THE GOOD
Mergers & Acquisitions

Willow Biosciences sold Epimeron USA to Mycofeast for US$2.76 million, with partial funds held in escrow until September
Platform technology, manufacturing - Read more

Vetirus Pharmaceuticals acquires regenerative medicine company Enso Discoveries, expanding its biologic therapy portfolio for human and veterinary health
Regenerative medicine, animal health - Read more

Granata Bio acquires Oviva Therapeutics, gaining OVI-586, an experimental therapy targeting ovarian aging to improve women's health
Fertility, women's health, ovarian aging - Read more

THE GOOD
Partnerships

Otsuka Pharmaceutical, ICU Medical, joint venture forms global IV solutions manufacturing network to enhance supply chain and introduce PVC-free technologies
Intravenous Solution, manufacturing, manufacturing partnership - Read more

Rein Therapeutics, Qureight, partnership integrates deep-learning platform for imaging analysis in IPF treatment trial
Clinical development, idiopathic pulmonary fibrosis, imaging, data analysis - Read more

TAE Life Sciences, Ohio State University, partnering to develop and evaluate boron-based drugs for Boron Neutron Capture Therapy cancer treatment
Small molecule, radiopharm, cancer, drug development, research & development - Read more

THE GOOD
Politics & Policy

Amgen executives advocate for tax incentives, not tariffs, to boost US pharmaceutical manufacturing, citing past success with Trump's tax cuts
Tariffs, domestic manufacturing, biotech ecosystem - Read more

THE GOOD
Research

Study shows 100% recovery of VSV virus from Turn Therapeutics' room-temperature oil carrier after 72 hours, making strides towards eliminating live-virus vaccine cold storage requirements
Vaccine, supply chain, cold chain, vaccine access - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA extends review of Cytokinetics' aficamten, a cardiac myosin inhibitor, for obstructive hypertrophic cardiomyopathy treatment to December 26, following REMS submission requirement
Small molecule, obstructive hypertrophic cardiomyopathy - Read more

THE BAD
Layoffs

Pliant Therapeutics cuts 45% of workforce to extend cash ahead of results from halted idiopathic pulmonary fibrosis drug study
Small molecule, idiopathic pulmonary fibrosis - Read more

THE BAD
Regulatory

FDA withdraws then reissues as drafts guidances for cell/tissue product donor eligibility following tuberculosis outbreak from bone allografts.
Tuberculosis, regulatory guidance, allograft, cell therapy, adverse effects - Read more [Paywall]

NIH ending foreign subawards, requiring direct funding for overseas partners with stricter tracking of grant funds.
National Institute of Health (NIH), federal research funding - Read more

THE BAD
Strategic Plans

Vertex Pharmaceuticals halts AAV vector delivery research for gene therapies despite maintaining commitment to cell and genetic therapies
Gene therapy, adeno-associated virus (AAV), Research & Development, pipeline strategy, drug delivery - Read more

Aera Therapeutics shifts from protein nanoparticles to older lipid nanoparticle technology for initial drug delivery programs
Lipid nanoparticle (LNP), drug delivery, protein nanoparticle, CRISPR, gene-editing - Read more [Paywall]

THE UGLY
Politics & Policy

White House budget proposes cutting NIH by $18B, CDC by $3.5B, while allocating $500M for Kennedy's "Make America Healthy Again" initiatives
National Institute of Health (NIH), Centers for Disease Control and Prevention (CDC) - Read more

Trump administration advocates for behavioral therapy over gender-affirming medical care for transgender youth in new HHS report
US Department of Health & Human Services (HHS), transgender - Read more

THE UGLY
Public Health

CDC reports 216 child flu deaths this season, the highest since the 2009-2010 H1N1 pandemic
Influenza, Infectious disease - Read more [Paywall]

Measles outbreaks accelerate in Canadian provinces Ontario and Alberta as vaccination rates drop below needed 95% threshold, prompting doctors' urgent calls for action
Vaccine, vaccine hesitancy, measles, infectious disease - Read more

THE UGLY
Regulatory

FDA drug reviewers asked to volunteer for administrative tasks after agency fired administrators and project managers last month
Drug approval process, Food & Drug Administration (FDA) - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here